View Author
patient tiotropium exacerbation study analysis value treatment hospital health group ipratropium method difference trial evaluation model disease cost-effectiveness probability number dropout resource resource use unit costs outcome ratio visit estimate treatment groups salmeterol distribution tiotropium group chapter result ipratropium group system dutch parameter cost data table state quality medication uncertainty ceiling ratio transition sample country netherland utility imputation price inpatient month improvement event information healthcare severity effect analyses period interval casemix curve approach bene fit upcoding score calculation cost-effectiveness analysis sensitivity kosten sensitivity analysis algorithm function simulation baseline data sets department
5 Most Recent Publications
|
Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research
(Article)
Oostenbrink, J.B. Al, M.J. Oppe, M. Rutten-van Mölken, M.P.M.H. |
2008-12-01
|
|
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
(Article)
Rutten-van Mölken, M.P.M.H. Oostenbrink, J.B. Miravitlles, M. Monz, B.U. |
2007-06-01
|
|
The risk of upcoding in casemix systems: A comparative study
(Article)
Steinbusch, P.J.M. Oostenbrink, J.B. Zuurbier, J.J. Schaepkens, F.J.M. |
2007-05-01
|
|
Principles and progress in healthcare cost analysis : applications to economic evaluations in COPD
(Doctoral Thesis)
Oostenbrink, J.B. |
2004-12-09
|
|
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
(Article)
Oostenbrink, J.B. Al, M.J. Noord, J.A. van Vincken, W. Rutten-van Mölken, M.P.M.H. |
2004-01-01
|